Ross
Well-known member
FDA and Aventis Pharmaceuticals revised the CLINICAL PHARMACOLOGY,
PRECAUTIONS, and DOSAGE AND ADMINISTRATION sections of labeling, describing
the need for a dosage adjustment for patients with severe renal impairment
(creatinine clearance <30mL/min) who have increased exposure to enoxaparin.
No specific dosage adjustment is required in patients with mild or moderate
renal impairment and in low-weight patients. However, low-weight patients
should be observed carefully for signs and symptoms of bleeding.
Read the MedWatch 2004 safety summary, including links to the "Dear
Healthcare Professional" letter and the revised professional labeling, at:
http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#lovenox
PRECAUTIONS, and DOSAGE AND ADMINISTRATION sections of labeling, describing
the need for a dosage adjustment for patients with severe renal impairment
(creatinine clearance <30mL/min) who have increased exposure to enoxaparin.
No specific dosage adjustment is required in patients with mild or moderate
renal impairment and in low-weight patients. However, low-weight patients
should be observed carefully for signs and symptoms of bleeding.
Read the MedWatch 2004 safety summary, including links to the "Dear
Healthcare Professional" letter and the revised professional labeling, at:
http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#lovenox